Raleigh, NC, September 10, 2025 —NuPulse, a medical device company focused on transforming the treatment of chronic heart failure with the NuPulse VoyageTM heart pump, today announced the appointment of Duane Pinto, MD, MPH, a leader in interventional cardiology, to its board of directors.
Dr. Pinto currently serves as Chief Medical Officer for JenaValve Technology, a medical device company focused on transcatheter heart valve solutions. Prior to joining JenaValve, Dr. Pinto served as Chief of Interventional Cardiology at Beth Israel Deaconess Medical Center and was an associate professor of Medicine at Harvard Medical School. Dr. Pinto’s medical career spans more than 20 years of performing complex coronary, structural, and peripheral vascular procedures with and without circulatory assistance. He has authored numerous device trials for both coronary and peripheral circulations and serves as a manuscript reviewer for NEJM, JACC, Circulation (AHA), and others and is on the editorial board of Circulation, CCI, and JACC.
“The NuPulse Voyage™ heart pump represents a breakthrough for patients living with chronic heart failure. It is the only cardiac assist device designed to be implanted in a minimally invasive way that allows patients to walk, rehabilitate, and even return home while supported by the device. I am excited to join NuPulse at this pivotal stage and contribute to advancing this important therapy for patients who need better options,” said Dr. Pinto.
“We are honored to welcome Dr. Pinto to our board. His expertise in interventional cardiology and leadership in advancing novel cardiovascular therapies will be invaluable as we prepare for the pivotal trial of the NuPulse Voyage™ heart pump,” said Douglas Altschuler, Chief Executive Officer of NuPulse.
About NuPulse
NuPulse is a privately held company focused on the development of innovative treatment options to radically impact treatment and outcomes for patients with chronic heart failure. The company’s patented device, the NuPulse Voyage, has completed a positive feasibility study and is poised to enter a pivotal trial to support product approval.
For more information, please visit www.nupulse.com and follow the company on LinkedIn @NuPulse.
Contact:
Investors & Media
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
Dr. Pinto currently serves as Chief Medical Officer for JenaValve Technology, a medical device company focused on transcatheter heart valve solutions. Prior to joining JenaValve, Dr. Pinto served as Chief of Interventional Cardiology at Beth Israel Deaconess Medical Center and was an associate professor of Medicine at Harvard Medical School. Dr. Pinto’s medical career spans more than 20 years of performing complex coronary, structural, and peripheral vascular procedures with and without circulatory assistance. He has authored numerous device trials for both coronary and peripheral circulations and serves as a manuscript reviewer for NEJM, JACC, Circulation (AHA), and others and is on the editorial board of Circulation, CCI, and JACC.
“The NuPulse Voyage™ heart pump represents a breakthrough for patients living with chronic heart failure. It is the only cardiac assist device designed to be implanted in a minimally invasive way that allows patients to walk, rehabilitate, and even return home while supported by the device. I am excited to join NuPulse at this pivotal stage and contribute to advancing this important therapy for patients who need better options,” said Dr. Pinto.
“We are honored to welcome Dr. Pinto to our board. His expertise in interventional cardiology and leadership in advancing novel cardiovascular therapies will be invaluable as we prepare for the pivotal trial of the NuPulse Voyage™ heart pump,” said Douglas Altschuler, Chief Executive Officer of NuPulse.
About NuPulse
NuPulse is a privately held company focused on the development of innovative treatment options to radically impact treatment and outcomes for patients with chronic heart failure. The company’s patented device, the NuPulse Voyage, has completed a positive feasibility study and is poised to enter a pivotal trial to support product approval.
For more information, please visit www.nupulse.com and follow the company on LinkedIn @NuPulse.
Contact:
Investors & Media
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com